The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML

Experimental Cell Research

Volumn 283, Issue 1, 2003, Pages 36-50

  Engelhardt, Othmar G ^a   Boutell, Chris ^b   Orr, Anne ^b   Ullrich, Evelyn ^a   Haller, Otto ^a   Everett, Roger D ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INSTITUTE OF VIROLOGY   (United Kingdom)

Author keywords

HIPK 2; ND10; PML nuclear bodies; Sp100; SUMO 1

Indexed keywords

GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE MX1; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; INTERFERON; PHOSPHOTRANSFERASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN HDAXX; PROTEIN ND10; PROTEIN SP100; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN STRUCTURE;

CRICETINAE;

EID: 0037330454     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00025-3     Document Type: Article

References (31)

1. Chelbi-Alix M., de The H. 10 years molecular APL: from RARα to PML nuclear bodies. Oncogene. 20:2001;. issue 49.
2. Kamitani T., Kito K., Nguyen H.P., Wada H., Fukuda-Kamitani T., Yeh E.T. Identification of three major sentrinization sites in PML. J. Biol. Chem. 273:1998;26675-26682.
3. Muller S., Matunis M.J., Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:1998;61-70.
4. Duprez E., Saurin A.J., Desterro J.M., Lallemand-Breitenbach V., Howe K., Boddy M.N., Solomon E., de The H., Hay R.T., Freemont P.S. SUMO-1 modification of the acute promyelocytic leukaemia protein PML implications for nuclear localisation . J. Cell Sci. 112:1999;381-393.
5. Everett R.D., Lomonte P., Sternsdorf T., van Driel R., Orr A. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112:1999;4581-4588.
6. Kim Y.H., Choi C.Y., Lee S.J., Conti M.A., Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273:1998;25875-25879.
7. Moilanen A.M., Karvonen U., Poukka H., Janne O.A., Palvimo J.J. Activation of androgen receptor function by a novel nuclear protein kinase. Mol. Biol. Cell. 9:1998;2527-2543.
8. Kim Y.H., Choi C.Y., Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc. Natl. Acad. Sci. USA. 96:1999;12350-12355.
9. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell. Biol. 4:2002;11-19.
10. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell. Biol. 4:2002;1-10.
11. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18:1999;6455-6461.
12. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18:1999;6462-6471.
13. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. USA. 97:2000;14145-14150.
14. Trost M., Kochs G., Haller O. Characterization of a novel serine/threonine kinase associated with nuclear bodies. J. Biol. Chem. 275:2000;7373-7377.
15. Engelhardt O.G., Ullrich E., Kochs G., Haller O. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies. Exp. Cell Res. 271:2001;286-295.
16. Minty A., Dumont X., Kaghad M., Caput D. Covalent modification of p73alpha by SUMO-1 two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif . J. Biol. Chem. 275:2000;36316-36323.
17. Kastner P., Perez A., Lutz Y., Rochette-Egly C., Gaub M.P., Durand B., Lanotte M., Berger R., Chambon P. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL) structural similarities with a new family of oncoproteins . EMBO J. 11:1992;629-642.
18. Boddy M.N., Howe K., Etkin L.D., Solomon E., Freemont P.S. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene. 13:1996;971-982.
19. Sternsdorf T., Guldner H.H., Szostecki C., Grotzinger T., Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol. 42:1995;257-268.
20. Grotzinger T., Sternsdorf T., Jensen K., Will H. Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur. J. Biochem. 238:1996;554-560.
21. Pluta A.F., Earnshaw W.C., Goldberg I.G. Interphase-specific association of intrinsic centromere protein CENP-C with HDaxx, a death domain-binding protein implicated in Fas-mediated cell death. J. Cell Sci. 111(Pt 14):1998;2029-2041.
22. Englert C., Hou X., Maheswaran S., Bennett P., Ngwu C., Re G.G., Garvin A.J., Rosner M.R., Haber D.A. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14:1995;4662-4675.
23. Saitoh H., Pu R., Cavenagh M., Dasso M. RanBP2 associates with Ubc9p and a modified form of RanGAP1. Proc. Natl. Acad. Sci. USA. 94:1997;3736-3741.
24. Sternsdorf T., Jensen K., Will H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell. Biol. 139:1997;1621-1634.
25. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss J.F., Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell. Biol. 147:1999;221-234.
26. Ahn J.H., Xu Y., Jang W.J., Matunis M.J., Hayward G.S. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 75:2001;3859-3872.
27. Muller S., Dejean A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:1999;5137-5143.
28. Parkinson J., Everett R.D. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74:2000;10006-10017.
29. Adamson A.L., Kenney S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2001;2388-2399.
30. Saitoh H., Pizzi M.D., Wang J. Perturbation of SUMOlation enzyme Ubc9 by distinct domain within nucleoporin RanBP2/Nup358. J. Biol. Chem. 277:2002;4755-4763.
31. Bell P., Lieberman P.M., Maul G.G. Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J. Virol. 74:2000;11800-11810.